SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is currently a focal point of market conversation as investors actively track ongoing takeover negotiations with a consortium including Stripe and Advent International, with the community pushing for a higher valuation than previous rejected offers. Shareholders are closely watching for any sign of a revised, more lucrative bid while balancing the stock's potential as a standalone entity fueled by its massive consumer network and aggressive share buyback program.

Chainlink is the industry-standard decentralized oracle network that solves the "oracle problem" by connecting smart contracts with real-world data. Blockchains cannot access external information on their own, so Chainlink acts as a secure bridge, enabling smart contracts to react to real-world events using verified, tamper-proof data. It is widely considered one of the first decentralized oracle networks and is the market leader in bringing off-chain data on-chain.  The platform operates through a decentralized network of nodes that fetch, validate, and deliver data to smart contracts. When a contract requests information like a stock price, a committee of independent nodes retrieves and aggregates the data to reach consensus, then delivers a single trustworthy answer. Chainlink offers a suite of services including Data Feeds for asset prices, CCIP for cross-chain token transfers and messaging, Automation for triggering smart contract functions, and Proof of Reserve for verifying asset collateralization.  Chainlink has established itself as critical infrastructure for both DeFi and institutional adoption, with partnerships including Swift, Euroclear, Mastercard, UBS, ANZ, Fidelity International, and J.P. Morgan. Its institutional products include the Chainlink Runtime Environment for tokenized asset workflows, Confidential Compute for privacy-preserving computation, and the Automated Compliance Engine for embedding regulatory rules into smart contracts.  The LINK token is the native asset used to pay node operators for services, fund subscription accounts, and incentivize network security through staking. Node operators stake LINK as collateral, which can be slashed if they provide inaccurate data. Chainlink was co-founded in 2017 by Sergey Nazarov and Steve Ellis, who co-authored the white paper with Ari Juels, and raised $32 million in its September 2017 ICO.

ChainLink

Chainlink is seeing increased market attention as community members debate its potential to serve as critical infrastructure for real-world asset tokenization and institutional financial data. While some investors remain skeptical about past performance, others are actively tracking its role alongside potential legislative clarity and cross-chain interoperability developments.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom shares faced a sharp pullback driven by a Bank of America analyst report highlighting potential long-term risks from off-balance-sheet AI financing, alongside broader investor anxiety regarding product margins and product mix. While the community is actively debating the significance of these debt concerns versus the company's elite EBITDA margins and growth prospects, bulls remain focused on the potential for a rebound ahead of upcoming earnings.

Wingstop, Inc. is a franchisor and chicken wings-focused restaurant. The firm is engaged in the flavor business offering cooked-to-order, hand-sauced, and tossed classic and boneless wings, tenders and chicken sandwiches in flavors, with signature sides, such as its seasoned fries and house made ranch and bleu cheese dips. The company was founded in 1994 and is headquartered in Dallas, TX.

Wingstop Inc

Wingstop is trending as investors debate the impact of broader consumer spending pressures and inflationary headwinds on its growth model, while the community remains divided between those viewing the recent share price decline as a long-term accumulation opportunity and those concerned about weakening same-store sales.

Penguin Solutions, Inc. engages in designing, building, and managing enterprise solutions. It operates through the following segments: Advanced Computing, Integrated Memory, and Optimized LED. The Advanced Computing segment offers platform solutions and services for artificial intelligence, high-performance computing, machine learning, advanced modeling, and the internet of things. The Integrated Memory refers to integrated memory solutions through the design and development. The Optimized LED segment comprises a broad portfolio of application-optimized LEDs. The company was founded in 1988 and is headquartered in Fremont, CA.

Penguin Solutions Inc.

Penguin Solutions ($PENG) is rallying following a record earnings beat and upward guidance revision, fueled by strong demand for its AI factory infrastructure and memory optimization solutions. While the community is actively debating the sustainability of this momentum, bulls are highlighting the company's role as a key NVIDIA partner, whereas skeptics are focusing on potential dilution risks from convertible notes and the stock's recent rapid valuation expansion.

OpenAI

OpenAI is trending as investors weigh its aggressive infrastructure scaling and IPO ambitions against rising internal pressure to prove profitability amid intensifying competition from rivals like Anthropic. While the community is debating executive turnover and potential valuation concerns, the company is attempting to pivot toward enterprise-focused revenue growth and efficiency to justify its status as a foundational AI leader.

PepsiCo, Inc. engages in the manufacture, marketing, distribution, and sale of beverages, food, and snacks. It operates through the following business segments: PepsiCo Foods North America (PFNA), PepsiCo Beverages North America (PBNA), International Beverages Franchise (IB Franchise), Europe, Middle East and Africa (EMEA), Latin America Foods (LatAm Foods), and Asia Pacific Foods. The PFNA segment refers to the food businesses in the United States and Canada. The PBNA segment includes beverage businesses in the United States and Canada. The IB Franchise segment involves the international franchise beverage businesses, as well as the SodaStream business. The EMEA segment pertains to food businesses and beverage businesses with company-owned bottlers in Europe, the Middle East, and Africa. The LatAm Foods segment consists of food businesses in Latin America. The Asia Pacific Foods segment is associated in food businesses in Asia Pacific, including China, Australia and New Zealand, as well as India. The company was founded by Donald M. Kendall, Sr. and Herman W. Lay in 1965 and is headquartered in Purchase, NY.

PepsiCo Inc

PepsiCo is trending as investors weigh its defensive status and reliable dividend growth against concerns over sluggish North American snack volumes and high input costs. The community is actively debating the company's long-term growth prospects, including speculation regarding potential acquisitions within the beverage and protein sectors.

Better Home & Finance Holding Co. engages in the provision of comprehensive homeownership services. It offers mortgage loans, real estate agent services, and title and homeowner's insurance services. The company was founded in 2014 and is headquartered in New York, NY.

Better Home & Finance Holding Co. - Ordinary Shares - Class A

Better Home & Finance Holding Co.

Better Home & Finance is experiencing significant volatility following a surprise leadership change as founder Vishal Garg stepped down in favor of interim CEO Daniel Lewis, fueling intense community speculation about a boardroom coup and potential privatization. Traders are closely monitoring the company's aggressive cost-cutting measures and the potential for a short squeeze as investors weigh the firm's pivot toward AI-driven infrastructure against its history of operational losses.

New Era Energy & Digital, Inc. is an exploration and production company, which engages in selling oil and natural gas products. The company was founded on February 6, 2023 and is headquartered in Midland, TX.

New Era Energy & Digital Inc.

Investors are actively debating the potential of New Era Energy & Digital as the company pivots toward becoming a data center power provider, fueled by significant institutional ownership and excitement over recently secured construction permits for its Texas site. While some community members are concerned by earnings misses and high cash burn, bulls are focusing on the strategic value of the project's 'behind-the-meter' power capabilities and ongoing negotiations for power purchase agreements.

Anthropic

Anthropic is actively preparing for a potential major IPO, with recent investor interest and strong enterprise revenue growth fueling anticipation for what could be a record-breaking public listing. The community is heavily focused on the company's competitive standing against OpenAI and the broader infrastructure race, with many discussing its potential valuation and strategic partnerships as key indicators of future market performance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters Option to Purchase Additional ADSs

Silence Therapeutics plc, (Nasdaq: SLN), (Silence or the Company), a global clinical-stage biotechnology company developing novel short interfering RNA (siRNA) therapies, today announced the closing of its previously announced underwritten public offering of 14,907,407 American Depositary Shares...

Wall Street Analysts Predict a 140.06% Upside in Silence Therapeutics (SLN): Here's  What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 140.1% in Silence Therapeutics (SLN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

The Catalysts are Back: Socket Mobile Breaks Out While Biotechs Race Toward Major Milestones

Today's action is being driven by a potent combination of corporate catalysts, clinical readouts and investor anticipation, with Socket Mobile (NASDAQ:SCKT) emerging as one of the session's standout movers while biotech names AbCellera Biologics (NASDAQ:ABCL), Silence Therapeutics (NASDAQ:SLN) and NeOnc Technologies (NASDAQ:NTHI) command attention around major clinical milestones.

Silence Therapeutics Says Blood Cancer Trial Delivers 'Best-Case Outcome'

Silence Therapeutics reports positive Phase 2 SANRECO trial data for divesiran in polycythemia vera. Phase 3 trial planned for 1H 2027.read more...

Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile

Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage biotechnology company developing novel siRNA (short interfering RNA) therapies, today announced positive topline results from the Phase 2 SANRECO trial of divesiran, a first-in-class siRNA, in 48 phlebotomy-dependent patients with...

Silence Therapeutics Hits the Catalyst Zone—Divesiran Data Could Send SLN Into Overdrive

Silence Therapeutics (NASDAQ:SLN) is heading into a potentially decisive moment as investors await topline results from the Phase 2 SANRECO trial of divesiran in polycythemia vera (PV). The company scheduled an August 10 conference call and webcast to discuss the results, putting its lead clinical program directly in the spotlight. With the Phase 2 study fully enrolled and topline data previously expected in the third quarter, the event represents a major potential inflection point for the clinical-stage biotech and its siRNA platform.

Silence Therapeutics Reports Second Quarter 2026 Financial and Business Results

Silence Therapeutics plc, (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial and business results for the second quarter ended June 30, 2026. Business Highlights Divesiran: First-in-class siRNA silencing TMPRSS6 for...

Silence Therapeutics shares surge ahead of divesiran Phase 2 results call

Silence Therapeutics shares surge ahead of divesiran Phase 2 results call...

Silence Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera

Silence Therapeutics plc, (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced a conference call and webcast to discuss topline results from the Phase 2 SANRECO trial of divesiran in polycythemia vera (PV) scheduled for tomorrow...

SLN Stock Skyrockets 107% in Six Months: Here's What You Need to Know

Silence Therapeutics shares surge as investors eye key 2026 divesiran data, an advancing RNAi pipeline and progress across multiple siRNA programs.

Silence Therapeutics Plc engages in the discovery, delivery, and development of ribonucleic acid (RNA) therapeutics. It also develops medicines by harnessing the body's natural mechanism of RNA interference within its cells. The company was founded on November 18, 1994 and is headquartered in London, the United Kingdom.

Silence Therapeutics Plc - ADR

Bullish Sentiment

Up more than 1% 

Flat to up 1%

Flat to down 1%

Down more than 1%

The S&P 500 ($SPY) is headed towards a winning week. What do you think the index's return will look like next week? Vote and explain your reasoning in the comments.

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Feed

News

Sentiment

Earnings

Fundamentals

Info

SLNSilence Therapeutics Plc - ADR

Fundamentals

Connect Stocktwits to ChatGPT

Latest SLN News